Biovica: Committed to developing and commercializing novel blood-based biomarker assays.
Biovica is a Swedish biotech company founded in 2009 with a vision to improve monitoring and predicting the efficacy of cancer therapies. Our initial focus is breast cancer, a disease responsible for over 685,000 deaths a year (BCRF, 2022). We work with leading cancer institutes, collaborative groups, and pharmaceutical companies on product development with the aim of improving outcomes and lowering costs.
Clinical validation: Our DiviTum® TKa test can detect an increase or decrease of Thymidine Kinase activity (TKa) level in the blood. This information can be used as an aid in monitoring disease progression. The DiviTum® TKa test was selected for support and funding by the European Commission Horizon 2020 phase 2 program. DiviTum® TKa test is FDA 510(k) cleared in the US and CE IVD labeled in the EU
| Site |
Badges |
|
|
Biovica Inc.
6195 Cornerstone Court E
San Diego, CA, 92121
United States
|
|
|
|
Biovica International AB
Dag Hammarshjöldsväg 54 B
Uppsala, , 75237
Sweden
|
|
|
|
San Diego CLIA lab
6195 Cornerstone Court E
San Diego, CA, 92121
United States
|
|
|
|
Uppsala Lab
Dag Hammarshjöldsväg 54 B
Uppsala, , 75237
Sweden
|
|